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http://dx.doi.org/10.1016/j.jmii.2013Allergic bronchopulmonary aspergillosis (ABPA) is a severe type of asthma. Some cases are
resistant to treatment, even with regular use of antiasthmatic drugs and antifungal agents.
The diagnosis of ABPA was made in a 40-year-old patient with ABPA according to the
Rosenberg-Patterson criteria. Symptoms were not controlled despite regular use of antiasth-
matic drugs, daily systemic steroids, and antifungal agents. Omalizumab, administered in an
attempt to stabilize these uncontrolled symptoms, was effective with no adverse events.
Our experience suggests omalizumab is a potential candidate drug for controlling steroid-
dependent ABPA.
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.10.003Introduction
The global prevalence of bronchial asthma in the adult
population is approximately 4% and has been increasing in
recent years.1 Approximately 5% of patients experience se-
vere asthmatic symptoms.1 Allergic bronchopulmonary
aspergillosis (ABPA) is a severe type of allergic asthma that
occurs in approximately 10% of patientswith severe asthma.2
ABPA, a complex clinical entity that results from an
innate allergic immune response to Aspergillus fumigatus
(AF), is mostly seen in patients with allergic asthma orhed by Elsevier Taiwan LLC. This is an open access article under the
4.0/).
Figure 1. Chest computed tomography obtained at the time
of diagnosis of allergic bronchopulmonary aspergillosis.
460 T. Homma et al.cystic fibrosis (CF).3 Sensitization of the allergic host to AF
leads to activation of Th2 lymphocytes, which play a key
role in allergic diseases, including asthma, by recruiting
inflammatory cells like mast cells and eosinophils.4 The
Rosenberg-Patterson criteria are most often used to di-
agnose ABPA.5
ABPA management starts with the avoidance of AF, with
antiasthmatic drugs and itraconazole (ITCZ) also being
effective in some cases.6 Systemic prednisolone (PSL) also
can be administered in severe cases. Recently, reports have
described positive results with the administration of oma-
lizumab, an anti-immunoglobulin (Ig) E drug, in adult pa-
tients with severe allergic asthma with or without CF.7,8
In this report, we describe an Asian case of noneCF-
related ABPA given anti-IgE therapy for longer than








Eosinophils (/mm3) 1011 988 964




ACT score 10 23 23
FEV1.0 (L) 1.89 1.96 1.91
%FEV1.0 54.1 55.9 54.7
FeNO (ppb) 43 23 25
Skin test to AF Positive Positive Negative
ACT Z Asthma Control Test; AF Z Aspergillus fumigatus;
FeNO Z fraction of exhaled nitric oxide; FEV1.0 Z forced
expiratory volume in 1 second; Ig Z immunoglobulin.Case Report
The current case was a 51-year-old Asian man in whom
ABPA was diagnosed at the age of 40 years. He had never
received a diagnosis of CF and had no familial history. At
the time of diagnosis, his percentage forced expiratory
volume in 1 second (FEV1.0) was 58.8%, reversible to 71.1%
(253 mL in absolute value) after inhalation of a short-acting
beta-agonist. All Rosenberg-Patterson diagnostic criteria
were met, including bronchiectasis with pulmonary in-
filtrates, particularly in the right upper lobe (Fig. 1). At the
time of diagnosis, his peripheral blood eosinophils were
1,358/mm3, total IgE level was 1,500 IU/mL, and AF-
specific IgE was 9.24 IU/mL. Precipitating antibody
against AF antigen was also found. The patient took PSL
regularly (10e20 mg/day) to control severe symptoms in
addition to other asthmatic medications (fluticasone
800 mg/day, salmeterol 100 mg/day, pranlukast 450 mg/day,
and theophylline 200 mg/day). We could not taper the PSL
dose because of frequent exacerbations. Oral ITCZ
(200 mg/day) was also administered for 6 months, but didnot reduce the annual exacerbation rate and was dis-
continued because of resulting liver damage (even with the
reduction of ITCZ to 100 mg/day). Because of frequent
exacerbations, we began administering 375 mg of omali-
zumab every 2 weeks starting at age 50 years. Asthmatic
symptoms improved after 2 months. After 4 months, we
evaluated the frequency of exacerbations, the Asthma
Control Test (ACT) score, pulmonary function, fraction of
exhaled nitric oxide (FeNO), peripheral blood eosinophils,
total IgE, and blood AF-specific IgE levels. The frequency of
major exacerbations was reduced from three to zero per
4 months, the ACT score changed from 10 to 23, FeNO
dropped from 43 ppb to 23 ppb, peripheral blood eosino-
phils changed from 1,011/mm3 to 988/mm3, total IgE
elevated from 677 IU/mL to 972 IU/mL, and AF-specific IgE
elevated from 7.73 IU/mL to 10.09 IU/mL. According to the
patient’s daily asthma self-assessment chart, frequency of
daytime or nighttime symptoms was reduced from nine to
three per fortnight, usage of a short-acting beta-agonist
was reduced from five to one per fortnight, and asthma-
related absentee rate improved from one incident to zero
per 4 months. During this treatment course, the patient was
not hospitalized for exacerbations, although his FEV1.0%
did not change from 54.1%.
After 12 months of treatment, the skin-prick test
became negative, serum total IgE decreased to 609 IU/mL,
and AF-specific IgE declined to 6.07 IU/mL (Table 1). With
levels of other antiasthmatic drugs remaining the same, we
were able to taper the daily PSL dose from 10 mg/day to
5 mg/day without incident. After 30 months of omalizumab
treatment, the exacerbation rate, ACT score, FeNO, pe-
ripheral blood eosinophils, total IgE, and AF-specific IgE
were maintained at good levels without additional PSL
administration.
Discussion
We have described an Asian case of ABPA without CF. The
patient met the ABPA diagnostic criteria with proximal
bronchiectasis, elevated serum IgE, serum precipitating
antibodies to AF, positive skin testing to AF, and had FEV1.0
Successful treatment of ABPA by omalizumab 461less than 60% of the predicted value. Systemic PSL treat-
ment therapy was maintained prior to, during, and after
the administration of omalizumab. Omalizumab treatment
was effective and resulted in no adverse events. We were
able to taper systemic PSL doses, and asthmatic symptoms
were dramatically improved. Skin tests for AF were nega-
tive after omalizumab administration. In addition, AF-
specific IgE titers also were decreased. Daily symptoms
showed amelioration, despite a lack of change in pulmo-
nary function assessments, such as %FEV1.0. Patient char-









1 44 M Hispanic American 20 mg 702
2 55 M Hispanic American 20 mg 586
3 44 F African American þ 4362
Without
CF
4 45 M Caucasian þ 1128
5 56 M Caucasian þ 565
6 58 F African American þ 863
7 53 F Not described 7.5 mg 3090
1 12 F Not described 50 mg 5200
2 12 M African American 20 mg 805
3 12 M Caucasian 1 mg/kg 2894
4 17 M Caucasian 10 mg 530
5 13 F Not described þ 947
6 14 M Not described þ 4261
With CF 7 14 F Not described þ 1526
8 14 M African American 5 mg 261
9 15 F Not described 7.5 mg 248
10 13 M Caucasian þ 1092
11 12 M Caucasian d 1782
12 14 M Not described þ 4388
13 15 M Not described þ 2884
# Average dose of daily PSL.
CF Z cystic fibrosis; F Z female; M Z male; PSL Z prednisolone.asthmatic symptoms may account for the lack of change in
%FEV1.0 following omalizumab treatment.9
Tillie-Leblond et al7 recently reported the effectiveness
of omalizumab in 16 adult patients with ABPA and without
CF. The details of our patient treated with omalizumab
essentially correspond to those of the patients reported:
reduction of daily PSL dose and fewer exacerbations of
asthmatic symptoms per year, but no changes in %FEV1.0.
Adding to the literature, we used the skin tests for AF to
measure the effect of omalizumab in our case. A novel
observation in the current study is that skin tests for AF were












24 mo Reduction Effective 19
375 mg
every 2 wk
24 mo No reduction Effective 19
375 mg
every 2 wk
12 mo Reduction Effective 20
375 mg
every 2 wk
12 mo Reduction Effective 20
375 mg
every 2 wk
12 mo Reduction Effective 20
375 mg
every 2 wk
12 mo Reduction Effective 20
375 mg
every 2 wk
12 mo Reduction Effective 21
300 mg
every 2 wk
6 wk Discontinued Effective 11
300 mg
every 2 wk
18 mo Discontinued Effective 12
375 mg
every 2 wk
18 mo Discontinued Effective 12
300 mg
every 2 wk
8 mo Discontinued Effective 12
300 mg
every 2 wk
11 mo Discontinued Effective 13
375 mg
every 2 wk
4 mo Discontinued Effective 14
375 mg
every 2 wk
4 mo Discontinued Effective 14
375 mg
every 2 wk
11 mo Discontinued Effective 15
300 mg
every 4 wk
12 mo Reduction Effective 16
450 mg
every 4 wk
18 mo Discontinued Effective 17
450 mg
every 2 wk





15 mo Discontinued Effective 18
300 mg
every 4 wk
17 mo Discontinued Effective 18
462 T. Homma et al.ABPA.10 According to past reports, many cases were able to
discontinue systemic PSL treatment completely, but in our
case only a PSL dose reduction was feasible. From the past
case reports, all patients with ABPA and CF were younger
than 20 years and 11 of 12 cases were able to discontinue
systemic PSL (Table 2).11e18 However, all patients with ABPA
and without CF were oral PSL-dependent and were only able
to reduce or maintain the dose of oral corticosteroids after
the omalizumab treatment.19e21 This implies that patients
with CF may have a better chance of discontinuing systemic
PSL than patients with noneCF-related ABPA. Also, it is
possible that patients with noneCF-related ABPA may
benefit from starting omalizumab therapy prior to becoming
PSL dependent. We do not believe that omalizumab was
ineffective in our case because asthmatic symptoms did
show amelioration. In addition, adrenal gland function may
be altered in patients with ABPA because of prolonged
administration of PSL. This might explain the difficulty with
PSL withdrawal for elderly patients. It is noteworthy that
most patients with ABPA and CF who were able to discon-
tinue systemic PSL were much younger than patients with
ABPA and without CF. These differences may reflect various
patient characteristics, such as age, CF complications, race,
diminished pulmonary function, and the period from the
diagnosis of asthma or ABPA until treatment.
Determining the omalizumab dose and dosing periodmight
be difficult in ABPA cases. In many Asian countries and the
United States when omalizumab was distributed for the first
time, it can only be administeredwhen IgE levels are between
30 IU/mL and 700 IU/mL in adults, and the maximum dose is
375mgevery2weeks. In theEuropeanUnion,omalizumabcan
be administered to a maximum of 1,500 IU/mL and the
maximum dose is 600 mg every 2 weeks. These differences
result in treatment limitations for asthmatic patients with
high levels of IgE, like those patients with ABPA. When
immunosuppressive agents such as PSL are administered, we
often see a decrease in total IgE level. This may lead to an
underestimation of the dose of omalizumab required for
treatment. In addition, PSL administration usually reduces
total IgE titers, but in some cases there is no decrease in AF-
specific IgE titers in clinical practice. This raises the possibility
that AF-specific IgE titers should be considered when deter-
mining the most appropriate doses of anti-IgE therapy for
patients with ABPA. From past case reports, CF-related cases
were observed up to 18 months, whereas noneCF-related
cases were observed for 24 months. In our case, wewere able
to continue omalizumab treatment for more than 30 months
without any adverse event. Some past cases showed deteri-
oration after discontinuation of omalizumab treatment.20
Because most noneCF-related cases were not able to dis-
continue systemic PSL during the omalizumab treatment,
discontinuation of omalizumab could lead to an unstable
control of asthma. Dose setting and dosing period in patients
taking PSL remains challenging, and further studies are
needed to resolve these problems.
The safety of administration of omalizumab to patients
with ABPA is a major concern. In addition to the risk of
anaphylaxis, the United States Food and Drug Administra-
tion advisory committee recently suggested that cardiac
and thromboembolic events may occur with increased fre-
quency in patients using omalizumab.22 At this time, based
on the limited evidence of its benefits, omalizumabtreatment is not uniformly recommended for all ABPA
cases. However, when a patient cannot tolerate the high
toxicity of PSL, as in our case, omalizumab administration
may be an option. For our patient and in published reports,
there were no obvious adverse events. Prospective studies
are needed to corroborate these largely retrospective
findings. Treatment remains unsatisfactory in many ABPA
cases. Although new agents offer promise, properly
controlled trials of their safety and efficacy are required.
In conclusion, when ITCZ efficacy is limited for the pa-
tient, omalizumab could be an alternative treatment with
the potential to reduce the long-term side effects of sys-
temic PSL. Well-designed prospective studies are needed to
fully assess the efficacy and toxicity of omalizumab in pa-
tients with ABPA.
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